TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33315051

Group type: EXPERIMENTAL
Intervention: AKB‐9778 (subcutaneous treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical ocular AKB‐9778
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AKB‐9778 (mechanistic studies in mice)
Number of subjects: 0
Study: 36147653

Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine plus bupivacaine (LB+B)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Ropivacaine plus dexamethasone (R+D)
Number of subjects: 89
Study: 33066972

Group type: EXPERIMENTAL
Intervention: Preoperative intravenous iron therapy
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study: 35886119

Group type: EXPERIMENTAL
Intervention: Ultra-endurance running (average of 4 ± 2 ultra-trails per year)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Long-distance running practice
Number of subjects: 66
Study: 34340632

Group type: EXPERIMENTAL
Intervention: Mental fatigue & self‐controlled feedback (MF&SCF)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Mental fatigue & yoked feedback (MF&Y)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: No mental fatigue & self‐controlled feedback (NMF&SCF)
Number of subjects: 44

Group type: COMPARATOR
Intervention: No mental fatigue & yoked feedback (NMF&Y)
Number of subjects: 44
Study: 32474433

Group type: EXPERIMENTAL
Intervention: ICMJE-member journals with explicit data-sharing policy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: ICMJE-affiliated journals with explicit data-sharing policy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: RCTs published in ICMJE-member journals
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: RCTs published in ICMJE-affiliated journals with explicit data-sharing policy
Number of subjects: 200
Study: 35438278

Group type: EXPERIMENTAL
Intervention: Vitamin C (2g 8 hourly) for five days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Thiamine (200 mg 12 hourly) for five days
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both Vitamin C and Thiamine for five days
Number of subjects: 80

Group type: COMPARATOR
Intervention: Neither Vitamin C nor Thiamine (control group)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 80
Study: 33128801

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 90
Study: 35713933

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 73

Group type: COMPARATOR
Intervention: Stretching-and-toning (active control)
Number of subjects: 73
Study: 36397218

Group type: EXPERIMENTAL
Intervention: Moxibustion treatment (once every other day, 3 times a week for 5 weeks)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional western medication therapy (control group)
Number of subjects: 70
Study: 32508339

Group type: EXPERIMENTAL
Intervention: Robot-assisted gait training (RAGT) with conventional physiotherapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Early start of RAGT
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Late start of RAGT
Number of subjects: 11
Study: 34323244

Group type: EXPERIMENTAL
Intervention: Sucralose
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Sucrose
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Stevia
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control (Sucrose)
Number of subjects: 138
Study: 36088747

Group type: EXPERIMENTAL
Intervention: Multi-modal intervention including lifestyle-related disease management, physical exercise, cognitive training, and nutritional counselling over 18 months.
Number of subjects: 200
Study: 32930519

Group type: EXPERIMENTAL
Intervention: Single Keraring segment implantation according to the Q-value-based nomogram (QN)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard manufacturer's nomogram (SN)
Number of subjects: 104
Study: 32452352

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXEQ4W)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every 2 weeks (ADAQ2W)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36448974

Group type: EXPERIMENTAL
Intervention: Intrathecal oxytocin (100 μg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 90
Study: 34315283

Group type: EXPERIMENTAL
Intervention: OPUS treatment after implementation
Number of subjects: 3328

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 3328
Study: 35182606

Group type: EXPERIMENTAL
Intervention: γ‐tACS of the cerebellum
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: γ‐tACS of the SMA
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: simultaneous stimulation of both regions
Number of subjects: 22
Study: 34276366

Group type: EXPERIMENTAL
Intervention: Norepinephrine (0.5 mg/h, maximum 3 mg/h) plus albumin (20–40 g/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midodrine (5 mg three times/day, maximum 12.5 mg three times/day) plus octreotide (100 μg/6 h, maximum 200 μg/6 h) plus albumin (20–40 g/day)
Number of subjects: 60
Study: 35065634

Group type: EXPERIMENTAL
Intervention: 200 IU of OXT vaginal gel daily for eight weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 33858230

Group type: EXPERIMENTAL
Intervention: Group A (interactive videos)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Group B (summary information with web-links)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study: 34495953

Group type: EXPERIMENTAL
Intervention: Clopidogrel use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 0
Study: 33109148

Group type: EXPERIMENTAL
Intervention: Oral health promotion program (biweekly group education sessions and a 12-week individual behavioral modification for oral hygiene course)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Oral health promotion program
Number of subjects: 68
Study: 34921230

Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: GOFL
Number of subjects: 55
Study: 33105418

Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula (HFNC) oxygenation (Optiflow)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nasal prongs
Number of subjects: 40
Study: 33297458

Group type: EXPERIMENTAL
Intervention: Multi-strain probiotic
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 34825740

Group type: EXPERIMENTAL
Intervention: PARO robot twice a day (Group 1)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PARO robot once a day (Group 2)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Plush-Toy (non-robotic PARO) once a day (Group 3)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: All groups (Group 1, Group 2, Group 3)
Number of subjects: 45
Study: 34108672

Group type: EXPERIMENTAL
Intervention: Vedolizumab 300 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Vedolizumab 600 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Vedolizumab (both dosages)
Number of subjects: 17
Study: 32513251

Group type: EXPERIMENTAL
Intervention: trastuzumab, pertuzumab, and eribulin mesylate
Number of subjects: 244

Group type: COMPARATOR
Intervention: trastuzumab, pertuzumab, and a taxane
Number of subjects: 244
Study: 33765841

Group type: EXPERIMENTAL
Intervention: Real-time functional magnetic resonance imaging neurofeedback
Number of subjects: 0
Study: 32108044

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (ICS) - 500 µg fluticasone propionate twice daily
Number of subjects: 751

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 751
Study: 32949568

Group type: EXPERIMENTAL
Intervention: Prolonged wireless reflux monitoring and a 3-week PPI cessation intervention
Number of subjects: 100
Study: 34143215

Group type: EXPERIMENTAL
Intervention: Left Ventricular (LV) compressions
Number of subjects: 34

Group type: COMPARATOR
Intervention: Traditional compressions
Number of subjects: 34
Study: 32058435

Group type: EXPERIMENTAL
Intervention: 5 days of daily chlorhexidine showers and mupirocin nasal ointment twice a day (for S. aureus carriers)
Number of subjects: 1318

Group type: COMPARATOR
Intervention: Control (S. aureus carriers)
Number of subjects: 1318

Group type: EXPERIMENTAL
Intervention: 5 days of daily chlorhexidine showers and mupirocin nasal ointment twice a day (for noncarriers)
Number of subjects: 1318

Group type: COMPARATOR
Intervention: Control (noncarriers)
Number of subjects: 1318
Study: 34256038

Group type: EXPERIMENTAL
Intervention: Bacopa monnieri
Number of subjects: 700000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700000
Study: 32978836

Group type: EXPERIMENTAL
Intervention: VR‐ToMIS
Number of subjects: 21

Group type: COMPARATOR
Intervention: Passive VR
Number of subjects: 21
Study: 32659714

Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 83
Study: 36352204

Group type: EXPERIMENTAL
Intervention: 0.5-mg pramipexole
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 34465833

Group type: EXPERIMENTAL
Intervention: Urea + Biochar (BC) (10 Mg ha-1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Urea + Biochar (BC) + Urease Inhibitor (UI) (1 L ton-1)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Urea (150 kg N ha-1)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Biochar (BC) (10 Mg ha-1)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Control
Number of subjects: 5
Study: 32755115

Group type: EXPERIMENTAL
Intervention: Anti-IL-5 treatments (mepolizumab, benralizumab, reslizumab)
Number of subjects: 10
Study: 34285768

Group type: EXPERIMENTAL
Intervention: Music therapy sessions (tr‐MI, N = 39)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Psychological treatment as usual (TAU, N = 35)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Music therapy sessions (tr‐MI)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Psychological treatment as usual (TAU)
Number of subjects: 74
Study: 32267934

Group type: COMPARATOR
Intervention: Triglycerides <1 mmol/L (<89 mg/dL)
Number of subjects: 108559

Group type: EXPERIMENTAL
Intervention: Triglycerides 2.0-2.9 mmol/L (177-265 mg/dL)
Number of subjects: 108559

Group type: EXPERIMENTAL
Intervention: Triglycerides 3.0-3.9 mmol/L (266-353 mg/dL)
Number of subjects: 108559

Group type: EXPERIMENTAL
Intervention: Triglycerides 4.0-4.9 mmol/L (354-442 mg/dL)
Number of subjects: 108559

Group type: EXPERIMENTAL
Intervention: Triglycerides ≥5 mmol/L (≥443 mg/dL)
Number of subjects: 108559

Group type: COMPARATOR
Intervention: Plasma triglycerides <2.0 mmol/L (77 mg/dL)
Number of subjects: 108559

Group type: EXPERIMENTAL
Intervention: Plasma triglycerides 2.0-4.9 mmol/L (177-442 mg/dL)
Number of subjects: 108559

Group type: EXPERIMENTAL
Intervention: Plasma triglycerides ≥5.0 mmol/L (443 mg/dL)
Number of subjects: 108559

Group type: COMPARATOR
Intervention: Remnant cholesterol <0.5 mmol/L (19 mg/dL)
Number of subjects: 108559

Group type: EXPERIMENTAL
Intervention: Remnant cholesterol 0.5-1.4 mmol/L (19-57 mg/dL)
Number of subjects: 108559

Group type: EXPERIMENTAL
Intervention: Remnant cholesterol ≥1.5 mmol/L (58 mg/dL)
Number of subjects: 108559

Group type: COMPARATOR
Intervention: Allele score 13-16
Number of subjects: 108559

Group type: EXPERIMENTAL
Intervention: Allele score 17-18
Number of subjects: 108559

Group type: EXPERIMENTAL
Intervention: Allele score 19-20
Number of subjects: 108559
Study: 36319912

Group type: EXPERIMENTAL
Intervention: Nefopam (20 mg in 100 mL normal saline)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Normal Saline (100 mL)
Number of subjects: 73
Study: 33586474

Group type: EXPERIMENTAL
Intervention: Take Charge intervention (one, two, or zero sessions)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Take Charge groups combined
Number of subjects: 400
Study: 36220712

Group type: EXPERIMENTAL
Intervention: Adoptive Immunotherapy with CD25/CD71 allodepleted donor T cells (ADTs)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Standard of care (Control)
Number of subjects: 21
Study: 33205343

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injections
Number of subjects: 32

Group type: COMPARATOR
Intervention: Saline injections (Control)
Number of subjects: 32
Study: 32147032

Group type: EXPERIMENTAL
Intervention: Intramuscular injections of 200000 IU vitamin D supplement (two injections, one at week 0 and another at week 4)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 50
Study: 33619983

Group type: EXPERIMENTAL
Intervention: Splint
Number of subjects: 159

Group type: COMPARATOR
Intervention: Splint-less
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Splint (preterms)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Splint-less (preterms)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Splint (across joints)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Splint-less (across joints)
Number of subjects: 159
Study: 34595577

Group type: COMPARATOR
Intervention: Autogenous bone graft from the zygomatic buttress (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1:1 mixture of autogenous bone graft and deproteinized porcine bone mineral (DPBM) (Test I)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Biphasic bone graft material (BBGM) (Test II)
Number of subjects: 60
Study: 32847127

Group type: EXPERIMENTAL
Intervention: Microprocessor knee 1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Microprocessor knee 2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison between microprocessor knee 1 and microprocessor knee 2
Number of subjects: 20
Study: 33301569

Group type: EXPERIMENTAL
Intervention: High frequency deep brain stimulation (DBS) at randomized different intensities
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High frequency deep brain stimulation (DBS)
Number of subjects: 16
Study: 32493398

Group type: EXPERIMENTAL
Intervention: Cyanoacrylate closure (VenaSeal™ closure system)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Surgical stripping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 0
Study: 35788212

Group type: EXPERIMENTAL
Intervention: Diacutaneous fibrolysis
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control limb (no treatment)
Number of subjects: 66
Study: 34251142

Group type: EXPERIMENTAL
Intervention: Use of telephone protocol
Number of subjects: 2498

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 2498
Study: 32219497

Group type: EXPERIMENTAL
Intervention: Metha (B‐Braun)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: SMF (Smith and Nephew)
Number of subjects: 36
Study: 35766592

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg propofol (group P)
Number of subjects: 102

Group type: COMPARATOR
Intervention: 1 mg/kg lidocaine 2% (group L)
Number of subjects: 102
Study: 33041226

Group type: EXPERIMENTAL
Intervention: Nintedanib
Number of subjects: 765
Study: 35919499

Group type: EXPERIMENTAL
Intervention: Probiotic group (50 patients) treated with Clostridium caseinate bifidobacterial probiotics
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional group (50 patients) receiving conventional treatment
Number of subjects: 100
Study: 34050539

Group type: EXPERIMENTAL
Intervention: Bayesian approach for sequentially monitoring phase II randomized clinical trials with noncompliance information.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bayesian additive regression trees for selecting baseline covariates and estimating complier average causal effect (CACE).
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision-making based on estimated CACE from accumulated data.
Number of subjects: 0
Study: 32819331

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) program covering six techniques in 4 sessions (30 min each), with or without pharmacotherapy.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail, but implied to be standard care or pharmacotherapy).
Number of subjects: 0
Study: 34850095

Group type: EXPERIMENTAL
Intervention: peficitinib
Number of subjects: 1052
Study: 33372675

Group type: EXPERIMENTAL
Intervention: tBRCA testing
Number of subjects: 1176

Group type: COMPARATOR
Intervention: gBRCA testing
Number of subjects: 1176
Study: 33156076

Group type: EXPERIMENTAL
Intervention: Microthin Descemet stripping automated endothelial keratoplasty (MT‐DSAEK)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Descemet membrane endothelial keratoplasty (DMEK)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Both groups (MT‐DSAEK and DMEK)
Number of subjects: 56
Study: 35082179

Group type: EXPERIMENTAL
Intervention: Laser-grooved treatment
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Sulfuric-acid-etched treatment
Number of subjects: 240

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 240

Group type: COMPARATOR
Intervention: Sandblasted treatment
Number of subjects: 240
Study: 34733185

Group type: EXPERIMENTAL
Intervention: Music Assisted Relaxation (MAR) protocol, a music therapy technique composed of entrained live music combined with a guided relaxation and/or the use of imagery
Number of subjects: 81

Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Music Assisted Relaxation (MAR) protocol
Number of subjects: 81
Study: 36119100

Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35801801

Group type: EXPERIMENTAL
Intervention: Oral sulfate tablet (OST)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG)
Number of subjects: 179
Study: 34140456

Group type: EXPERIMENTAL
Intervention: Telemonitoring-supported exercise training for 6 months
Number of subjects: 314

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 314
Study: 32643857

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg)
Number of subjects: 12637

Group type: EXPERIMENTAL
Intervention: Semaglutide (0.5-1.0 mg)
Number of subjects: 12637

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12637
Study: 35799662

Group type: EXPERIMENTAL
Intervention: Vaginoscopy
Number of subjects: 125

Group type: COMPARATOR
Intervention: Conventional Hysteroscopy
Number of subjects: 125
Study: 33906741

Group type: EXPERIMENTAL
Intervention: Urban children
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Rural children
Number of subjects: 557

Group type: COMPARATOR
Intervention: Rural households cooking outside
Number of subjects: 557

Group type: COMPARATOR
Intervention: Rural households supervising older children
Number of subjects: 557
Study: 33588633

Group type: EXPERIMENTAL
Intervention: Healthy Schools Healthy Communities (HSHC) initiative
Number of subjects: 0
Study: 32157599

Group type: EXPERIMENTAL
Intervention: DB-020 (sodium thiosulfate pentahydrate in 1% sodium hyaluronate) administered via intratympanic injection
Number of subjects: 5
Study: 35121623

Group type: EXPERIMENTAL
Intervention: Abemaciclib plus Fulvestrant
Number of subjects: 669

Group type: COMPARATOR
Intervention: Placebo plus Fulvestrant
Number of subjects: 669
Study: 32080811

Group type: EXPERIMENTAL
Intervention: 650 mg of PL-ASA in fasted state
Number of subjects: 20

Group type: COMPARATOR
Intervention: 650 mg of PL-ASA in fed state
Number of subjects: 20
Study: 35946981

Group type: EXPERIMENTAL
Intervention: Tretinoin 0.05% lotion (Altreno)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Generic 0.05% cream
Number of subjects: 25
Study: 35337317

Group type: EXPERIMENTAL
Intervention: Objective Structured Clinical Examination (OSCE) assessment method for Kampo medicine
Number of subjects: 11
Study: 32350185

Group type: EXPERIMENTAL
Intervention: Topical 5% zinc oxide paste, applied trice daily after food for the entire treatment period, initiated 2 days prior to radiotherapy.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Improvised zinc preparation (1%), applied trice daily after food for the entire treatment period, initiated 2 days prior to radiotherapy.
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Improvised zinc preparation (1%)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Standard treatment offered by cancer hospital (Control group)
Number of subjects: 75
Study: 33775047

Group type: EXPERIMENTAL
Intervention: Artificial intelligence prediction model for inherited metabolic diseases
Number of subjects: 5907547

Group type: COMPARATOR
Intervention: Clinicians' detection
Number of subjects: 5907547

Group type: EXPERIMENTAL
Intervention: Artificial intelligence prediction model
Number of subjects: 5907547

Group type: EXPERIMENTAL
Intervention: Artificial intelligence model
Number of subjects: 5907547
Study: 36062848

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Dilemma‐focused therapy
Number of subjects: 116

Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 116
Study: 34281789

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Dietary energy intake
Number of subjects: 287
Study: 32687088

Group type: EXPERIMENTAL
Intervention: Miniaturized cardiopulmonary bypass (MCPB)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Conventional cardiopulmonary bypass (CCPB)
Number of subjects: 71

Group type: COMPARATOR
Intervention: CCPB
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: MCPB
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: MCPB and CCPB
Number of subjects: 71
Study: 35555631

Group type: EXPERIMENTAL
Intervention: Morning mindfulness meditation (24 minutes)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Evening mindfulness meditation (24 minutes)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both morning and evening meditation
Number of subjects: 16
Study: 33140403

Group type: EXPERIMENTAL
Intervention: MDZ‐NS 5 mg
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 34226609

Group type: EXPERIMENTAL
Intervention: Fertilization
Number of subjects: 0
Study: 33897217

Group type: EXPERIMENTAL
Intervention: Community perception and attitude towards people with depression
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Preferred treatment for people with depression
Number of subjects: 617

Group type: EXPERIMENTAL
Intervention: Factors affecting community attitude
Number of subjects: 617